Recombinant Human Anti-CD89 x Human Anti-HIV-1 gp41 Bispecific Antibody (scFv-Fc-scFv) (BSTF-H306)

Recombinant Anti-CD89 x Anti-HIV-1 gp41 Bispecific Antibody (scFv-Fc-scFv) is designed to be expressed as one chain, then assembled to a homodimer of bivalent scFv fragments and the Fc region of IgG. The anti-CD89 scFv is fused to the N-terminus of Fc via a hinge region while another anti-HIV-1 gp41 scFv is linked to the C-terminus of Fc. This scFv-Fc-scFv format has 2+2 antigen-binding valency by employing different scFv fragments. This BsAb can retarget macrophages to tumor cells. It is designed for the research of HIV-1 infection, AIDS therapy.

Datasheet INQUIRY

Specifications

Targets

CD89 & HIV-1 gp41

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

HIV-1 infection, AIDS

Targets

Target 1

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Target 2

HIV-1 gp41

Gene ID

155971

UniProt ID

Q0H5Z9

Alternative Names

ENV; gp160; Envelope glycoprotein 120; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain; human immunodeficiency virus type 1; human immunodeficiency virus type 1 gp120; human immunodeficiency virus type 1 glycoprotein 120; gp41; GP41; glycoprotein 41

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD89 x Human Anti-HIV-1 gp41 Bispecific Antibody (scFv-Fc-scFv) (BSTF-H306). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD89 x Human Anti-HIV-1 gp41 Bispecific Antibody (scFv-Fc-scFv) (CAT#: BSTF-H306)

Specifications

Targets

Customer Reviews and Q&As